The Frequency of Specific KRAS Mutations, and Their Impact on Treatment Choice and Survival, in Patients With Metastatic Colorectal Cancer.
Ana Fernández MontesVicente Alonso OrduñaElena Asensio MartínezNuria Rodríguez SalasEsperanza TorresDiego Cacho LavínRosa María Rodríguez AlonsoEsther FalcóJoan Carles OlivaLluis CireraJesus García GómezCarles PericayPublished in: The oncologist (2023)
These findings confirm that KRAS mutation location may predict survival outcomes in patients with mCRC, and suggest that pre-/post-operative bevacizumab plus metastasectomy provides survival benefits in patients with KRAS mutations.